Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free CRDF Stock Alerts

Cardiff Oncology (CRDF) Financials

Cardiff Oncology logo
$0.87 -0.01 (-1.66%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$0.90 +0.03 (+3.03%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Cardiff Oncology

Annual Income Statements for Cardiff Oncology

This table shows Cardiff Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -27 -39 -25 -19 -17 -23 -28 -39 -41 -45 -46
Consolidated Net Income / (Loss)		 -27 -39 -25 -16 -16 -19 -28 -39 -41 -45 -46
Net Income / (Loss) Continuing Operations		 -27 -39 -25 -16 -16 -19 -28 -39 -41 -45 -46
Total Pre-Tax Income 		-27 -39 -23 -16 -16 -19 -28 -39 -41 -45 -46
Total Operating Income		 -25 -40 -26 -17 -17 -19 -29 -40 -45 -49 -49
Total Gross Profit		 -0.32 -1.35 -1.31 -0.22 0.24 0.37 0.36 0.39 0.49 0.68 0.59
Total Revenue		 0.31 0.38 0.51 0.38 0.24 0.37 0.36 0.39 0.49 0.68 0.59
Operating Revenue		 0.29 0.34 0.51 0.38 0.24 0.37 0.36 0.39 0.49 0.68 0.59
Total Cost of Revenue		 0.63 1.73 1.81 0.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 25 39 24 17 17 19 29 40 46 49 50
Selling, General & Admin Expense		 7.92 11 14 8.01 5.76 8.22 12 13 13 12 14
Research & Development Expense		 11 15 7.88 8.16 11 11 17 27 33 37 35
Total Other Income / (Expense), net		 -2.19 1.09 2.52 0.81 0.26 -0.19 0.56 1.20 3.97 3.22 3.11
Interest & Investment Income		 - 0.30 0.15 0.22 0.23 0.09 0.26 1.58 4.07 3.26 3.10
Other Income / (Expense), net		 -0.73 2.46 3.40 0.62 0.03 -0.28 0.30 -0.38 -0.10 -0.04 0.01
Preferred Stock Dividends Declared		 0.02 0.02 0.02 2.79 0.29 3.29 0.02 0.02 0.02 0.02 0.03
Basic Earnings per Share		 ($1.05) ($1.30) ($51.76) ($8.26) ($2.80) ($1.08) ($0.73) ($0.89) ($0.93) ($0.95) ($0.69)
Weighted Average Basic Shares Outstanding		 26.20M 30.17M 481.67K 2.33M 5.97M 20.88M 39.03M 43.60M 44.68M 47.65M 66.84M
Diluted Earnings per Share		 ($1.21) ($1.37) ($51.76) ($8.26) ($2.80) ($1.08) ($0.73) ($0.89) ($0.93) ($0.95) ($0.69)
Weighted Average Diluted Shares Outstanding		 26.45M 30.28M 481.67K 2.33M 5.97M 20.88M 39.03M 43.60M 44.68M 47.65M 66.84M
Weighted Average Basic & Diluted Shares Outstanding		 29.76M 30.97M 55.29M 2.33M 5.97M 20.87M 43.31M 44.68M 44.68M 66.52M 68.36M

Quarterly Income Statements for Cardiff Oncology

This table shows Cardiff Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.74 -9.34 -10 -12 -12 -12 -13 -14 -11 -7.22 -12
Consolidated Net Income / (Loss)		 -9.73 -9.34 -10 -12 -12 -12 -13 -14 -11 -7.22 -12
Net Income / (Loss) Continuing Operations		 -9.73 -9.34 -10 -12 -12 -12 -13 -14 -11 -7.22 -12
Total Pre-Tax Income 		-9.73 -9.34 -10 -12 -12 -12 -13 -14 -11 -7.22 -12
Total Operating Income		 -11 -10 -11 -13 -13 -13 -14 -15 -12 -7.83 -13
Total Gross Profit		 0.14 0.16 0.21 0.16 0.17 0.15 0.11 0.12 0.12 0.24 0.04
Total Revenue		 0.14 0.16 0.21 0.16 0.17 0.15 0.11 0.12 0.12 0.24 0.04
Operating Revenue		 0.14 0.16 0.21 0.16 0.17 0.15 0.11 0.12 0.12 0.24 0.04
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 11 10 11 13 13 13 14 15 12 8.07 13
Selling, General & Admin Expense		 2.94 2.73 3.13 3.22 3.13 3.01 4.01 3.32 3.90 3.00 6.13
Research & Development Expense		 8.02 7.76 8.01 9.49 9.64 9.71 10 12 8.20 5.08 6.77
Total Other Income / (Expense), net		 1.09 1.00 0.92 0.77 0.75 0.79 0.95 0.83 0.72 0.61 0.51
Interest & Investment Income		 1.07 1.01 0.93 0.81 0.74 0.79 0.94 0.84 0.72 0.61 0.51
Other Income / (Expense), net		 0.02 -0.01 -0.00 -0.04 0.01 -0.00 0.01 -0.00 0.00 -0.00 -0.00
Preferred Stock Dividends Declared		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Basic Earnings per Share		 ($0.22) ($0.21) ($0.22) ($0.26) ($0.25) ($0.22) ($0.20) ($0.21) ($0.17) ($0.11) ($0.18)
Weighted Average Basic Shares Outstanding		 44.68M 44.68M 44.68M 44.83M 46.87M 47.65M 66.52M 66.53M 66.88M 66.84M 68.35M
Diluted Earnings per Share		 ($0.22) ($0.21) ($0.22) ($0.26) ($0.25) ($0.22) ($0.20) ($0.21) ($0.17) ($0.11) ($0.18)
Weighted Average Diluted Shares Outstanding		 44.68M 44.68M 44.68M 44.83M 46.87M 47.65M 66.52M 66.53M 66.88M 66.84M 68.35M
Weighted Average Basic & Diluted Shares Outstanding		 44.68M 44.68M 44.72M 46.55M 51.13M 66.52M 66.53M 66.53M 67.36M 68.36M 68.37M

Annual Cash Flow Statements for Cardiff Oncology

This table details how cash moves in and out of Cardiff Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 40 -54 -5.69 3.23 -1.26 121 -119 4.40 5.31 30 -34
Net Cash From Operating Activities		 -22 -31 -23 -13 -13 -16 -23 -34 -31 -38 -38
Net Cash From Continuing Operating Activities		 -22 -31 -23 -13 -13 -16 -23 -34 -31 -38 -38
Net Income / (Loss) Continuing Operations		 -27 -39 -25 -16 -16 -19 -28 -39 -41 -45 -46
Consolidated Net Income / (Loss)		 -27 -39 -25 -16 -16 -19 -28 -39 -41 -45 -46
Depreciation Expense		 0.38 1.07 1.25 0.86 0.49 0.47 0.45 0.24 0.40 0.40 0.36
Amortization Expense		 0.35 0.28 0.12 - - 0.00 1.61 0.63 -0.92 -0.06 -0.85
Non-Cash Adjustments To Reconcile Net Income		 4.04 8.39 6.92 2.71 1.11 3.22 5.87 4.94 5.05 4.76 6.23
Changes in Operating Assets and Liabilities, net		 0.59 -1.57 -6.67 -0.30 1.54 -0.69 -2.68 -0.93 6.03 2.63 2.18
Net Cash From Investing Activities		 -2.23 -25 24 0.02 -0.07 -0.21 -131 38 36 14 1.34
Net Cash From Continuing Investing Activities		 -2.23 -25 24 0.02 -0.07 -0.21 -131 38 36 14 1.34
Purchase of Property, Plant & Equipment		 -2.24 -0.82 -0.10 -0.01 -0.07 -0.21 -0.21 -1.01 -0.58 -0.08 -0.04
Purchase of Investments		 0.00 -38 -8.80 -0.03 - 0.00 -174 -91 -70 -24 -72
Sale and/or Maturity of Investments		 0.00 14 33 0.03 - 0.00 43 130 107 37 73
Net Cash From Financing Activities		 65 2.30 -6.38 16 12 137 35 0.08 0.00 54 2.58
Net Cash From Continuing Financing Activities		 65 2.30 -6.38 16 12 137 35 0.08 0.00 54 2.58
Issuance of Common Equity		 61 2.36 12 12 8.82 112 34 - 0.00 53 0.00
Other Financing Activities, net		 2.25 0.37 0.00 1.61 3.30 25 1.26 0.08 0.00 0.37 2.58
Cash Income Taxes Paid		 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00

Quarterly Cash Flow Statements for Cardiff Oncology

This table details how cash moves in and out of Cardiff Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.14 6.42 -3.00 6.84 -12 38 -27 -13 -0.65 7.34 -8.93
Net Cash From Operating Activities		 -7.96 -7.14 -7.74 -9.23 -10 -10 -13 -8.33 -11 -5.97 -12
Net Cash From Continuing Operating Activities		 -7.96 -7.14 -7.74 -9.23 -10 -10 -13 -8.33 -11 -5.97 -12
Net Income / (Loss) Continuing Operations		 -9.73 -9.34 -10 -12 -12 -12 -13 -14 -11 -7.22 -12
Consolidated Net Income / (Loss)		 -9.73 -9.34 -10 -12 -12 -12 -13 -14 -11 -7.22 -12
Depreciation Expense		 0.11 0.10 0.10 0.11 0.10 0.10 0.09 0.09 0.09 0.09 0.09
Amortization Expense		 -0.31 -0.21 -0.02 0.01 -0.02 -0.16 -0.00 -0.17 -0.12 -0.56 0.04
Non-Cash Adjustments To Reconcile Net Income		 1.09 1.04 1.12 1.18 1.25 1.34 1.37 1.68 1.38 1.80 1.66
Changes in Operating Assets and Liabilities, net		 0.89 1.26 1.07 1.26 0.07 0.24 -0.82 4.00 -0.93 -0.08 -1.73
Net Cash From Investing Activities		 3.82 14 4.64 14 -9.43 4.51 -15 -4.98 10 11 3.26
Net Cash From Continuing Investing Activities		 3.82 14 4.64 14 -9.43 4.51 -15 -4.98 10 11 3.26
Purchase of Property, Plant & Equipment		 -0.32 -0.01 -0.08 - - - 0.00 -0.03 -0.02 - 0.00
Purchase of Investments		 -17 -2.59 -0.92 - -23 - -36 -20 -9.34 -6.72 -13
Sale and/or Maturity of Investments		 21 16 5.64 14 13 4.51 21 15 20 17 16
Net Cash From Financing Activities		 - - 0.11 2.06 7.43 44 0.00 - 0.03 2.55 0.11
Net Cash From Continuing Financing Activities		 - - 0.11 2.06 7.43 44 0.00 - 0.03 2.55 0.11
Issuance of Common Equity		 - - - - 7.43 44 0.00 - - - 0.00
Other Financing Activities, net		 - - 0.11 0.25 - 0.01 0.00 - 0.03 2.55 0.11

Annual Balance Sheets for Cardiff Oncology

This table presents Cardiff Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 71 44 12 14 13 135 150 116 82 97 62
Total Current Assets		 68 39 9.47 13 11 133 146 111 77 95 60
Cash & Equivalents		 67 14 8.23 11 10 131 12 16 22 51 17
Short-Term Investments		 0.00 24 - - - 0.00 129 89 53 40 41
Accounts Receivable		 0.10 0.10 0.08 0.17 0.20 0.32 0.54 0.77 0.29 0.77 0.18
Prepaid Expenses		 0.79 0.96 1.17 1.14 0.95 2.06 4.77 5.25 2.30 2.54 1.64
Plant, Property, & Equipment, net		 2.69 3.83 2.43 1.30 0.88 0.62 0.38 1.27 1.24 0.90 0.58
Total Noncurrent Assets		 0.37 1.17 0.39 0.10 0.85 0.75 3.04 3.64 2.99 1.24 1.18
Other Noncurrent Operating Assets		 0.37 1.17 0.39 0.10 0.85 0.75 3.04 3.64 2.99 1.24 1.18
Total Liabilities & Shareholders' Equity		 71 44 12 14 13 135 150 116 82 97 62
Total Liabilities		 23 24 5.78 4.09 5.78 6.57 9.13 9.85 12 14 16
Total Current Liabilities		 8.20 7.80 3.95 2.92 4.78 6.12 6.56 7.81 10 13 16
Accounts Payable		 1.04 1.13 0.83 0.66 0.66 1.37 1.44 1.96 1.97 4.82 8.09
Accrued Expenses		 1.90 4.02 1.45 1.77 3.26 3.85 4.53 5.18 7.78 7.90 7.58
Other Current Liabilities		 - - - 0.00 0.87 0.90 0.59 0.68 0.69 0.71 0.73
Total Noncurrent Liabilities		 15 16 1.83 1.16 0.99 0.45 2.57 2.04 1.46 0.81 0.10
Other Noncurrent Operating Liabilities		 3.30 0.83 0.65 0.07 0.99 0.45 2.57 2.04 1.46 0.81 0.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 49 20 6.51 10 7.31 128 140 106 70 83 45
Total Preferred & Common Equity		 49 20 6.51 10 7.31 128 140 106 70 83 45
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 49 20 6.51 10 7.31 128 140 106 70 83 45
Common Stock		 158 168 180 202 217 362 401 405 409 467 475
Retained Earnings		 -109 -148 -173 -192 -209 -231 -260 -298 -340 -384 -430
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 - - - 0.00 -0.14 -0.40 -0.07 0.03 0.05

Quarterly Balance Sheets for Cardiff Oncology

This table presents Cardiff Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 88 74 66 63 85 76 64 49
Total Current Assets		 84 70 62 59 83 74 62 47
Cash & Equivalents		 15 19 26 13 24 11 10 8.54
Short-Term Investments		 66 49 35 45 56 60 50 38
Accounts Receivable		 0.20 0.39 0.45 0.62 0.41 0.53 0.25 0.19
Prepaid Expenses		 2.34 2.41 1.48 1.05 2.42 2.21 0.96 1.10
Plant, Property, & Equipment, net		 1.32 1.20 1.10 0.99 0.81 0.74 0.67 0.49
Total Noncurrent Assets		 3.23 2.85 2.71 2.57 1.29 1.30 1.31 1.34
Other Noncurrent Operating Assets		 3.23 2.85 2.71 2.57 1.29 1.30 1.31 1.34
Total Liabilities & Shareholders' Equity		 88 74 66 63 85 76 64 49
Total Liabilities		 11 13 14 14 14 17 15 14
Total Current Liabilities		 9.02 12 13 13 13 17 15 14
Accounts Payable		 2.18 5.19 5.11 4.64 3.63 6.01 2.44 5.48
Accrued Expenses		 6.15 5.96 6.71 7.18 8.95 9.94 12 8.34
Other Current Liabilities		 0.69 0.70 0.70 0.71 0.72 0.72 0.73 0.65
Total Noncurrent Liabilities		 1.61 1.30 1.14 0.98 0.64 0.46 0.28 0.00
Other Noncurrent Operating Liabilities		 1.61 1.30 1.14 0.98 0.64 0.46 0.28 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 78 61 52 49 71 59 49 35
Total Preferred & Common Equity		 78 61 52 49 71 59 49 35
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 78 61 52 49 71 59 49 35
Common Stock		 408 410 413 422 468 470 472 477
Retained Earnings		 -330 -349 -361 -372 -398 -412 -423 -442
Accumulated Other Comprehensive Income / (Loss)		 -0.41 -0.13 -0.10 0.08 0.03 0.02 0.05 -0.05

Annual Metrics And Ratios for Cardiff Oncology

This table displays calculated financial ratios and metrics derived from Cardiff Oncology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 29,722,602.00 30,615,406.00 38,106,460.00 22,990,942.00 7,742,355.00 35,324,607.00 39,552,129.00 44,677,169.00 44,677,169.00 - 67,360,564.00
DEI Adjusted Shares Outstanding		 412,814.00 425,214.00 529,256.00 3,831,824.00 7,742,355.00 35,324,607.00 39,552,129.00 44,677,169.00 44,677,169.00 - 67,360,564.00
DEI Earnings Per Adjusted Shares Outstanding		 -66.60 -92.25 -47.11 -5.03 -2.16 -0.64 -0.72 -0.87 -0.93 - -0.68
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11.65% 21.82% 32.63% -25.14% -35.34% 49.61% -1.91% 7.52% 26.42% 39.96% -13.18%
EBITDA Growth		 -93.89% -43.75% 42.69% 25.20% -3.71% -17.00% -40.19% -48.76% -16.78% -6.19% -2.26%
EBIT Growth		 -92.32% -44.94% 41.10% 25.94% -1.29% -16.33% -47.44% -41.08% -12.97% -6.99% -0.54%
NOPAT Growth		 -69.11% -58.84% 36.24% 33.37% 2.20% -14.43% -51.18% -38.28% -13.81% -7.13% -0.64%
Net Income Growth		 -91.76% -42.71% 36.47% 33.91% 0.29% -17.62% -46.53% -36.81% -7.07% -9.63% -0.92%
EPS Growth		 -37.50% -13.22% 36.47% 33.91% 66.10% 61.43% 32.41% -21.92% -4.49% -2.15% 27.37%
Operating Cash Flow Growth		 -73.79% -40.33% 25.00% 43.31% -0.52% -22.97% -41.22% -46.79% 8.67% -22.04% -0.61%
Free Cash Flow Firm Growth		 -69.97% -48.90% 33.70% 42.69% 7.27% -32.10% -68.52% -30.04% 12.86% -18.39% 0.63%
Invested Capital Growth		 41.90% 31.52% 75.57% -252.69% -110.67% 2.11% 85.69% 366.34% -572.49% -73.03% -46.82%
Revenue Q/Q Growth		 7.85% -2.83% 30.11% -22.05% 6.33% 7.78% 4.06% -1.28% 6.09% -0.87% 18.60%
EBITDA Q/Q Growth		 -11.98% -2.03% 20.59% -13.08% -1.62% -13.92% -10.29% -1.14% -2.35% -4.69% 8.74%
EBIT Q/Q Growth		 -11.62% -2.70% 20.14% -11.31% -1.35% -13.51% -11.37% 0.18% -2.04% -4.80% 8.84%
NOPAT Q/Q Growth		 -12.86% -6.35% 18.98% -1.91% -1.13% -13.08% -11.73% 0.33% -2.11% -4.83% 8.84%
Net Income Q/Q Growth		 -10.89% -3.07% 19.36% -10.68% -0.51% -13.89% -11.18% 1.89% -1.57% -5.70% 9.07%
EPS Q/Q Growth		 -39.08% -9.60% 19.36% -10.68% -1.45% -24.14% -14.06% 5.32% -1.09% -1.06% 13.75%
Operating Cash Flow Q/Q Growth		 -15.34% -7.61% 19.59% -2.18% 2.47% -12.77% -10.91% -6.29% 6.79% -9.05% 10.18%
Free Cash Flow Firm Q/Q Growth		 -23.13% -8.09% 19.98% 13.24% 0.93% -15.57% -12.23% -7.20% 10.66% -9.35% 11.49%
Invested Capital Q/Q Growth		 42.40% 57.92% 80.61% -26.04% -21.37% -9.51% 19.68% 198.63% -43.78% -6.31% -9.45%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -101.14% -354.12% -258.41% -57.92% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -8,080.00% -9,534.38% -4,120.30% -4,117.32% -6,603.43% -5,164.21% -7,380.78% -10,211.66% -9,432.99% -7,157.25% -8,337.10%
Operating Margin		 -8,079.50% -10,534.91% -5,064.42% -4,507.61% -6,817.79% -5,214.75% -8,037.60% -10,337.31% -9,305.74% -7,123.13% -8,256.32%
EBIT Margin		 -8,311.72% -9,888.81% -4,391.48% -4,344.50% -6,805.46% -5,291.53% -7,954.04% -10,436.53% -9,325.82% -7,128.84% -8,255.48%
Profit (Net Income) Margin		 -8,781.98% -10,287.75% -4,928.09% -4,351.07% -6,709.74% -5,275.14% -7,880.50% -10,026.94% -8,492.01% -6,651.68% -7,732.04%
Tax Burden Percent		 100.01% 100.37% 107.91% 101.35% 100.00% 100.15% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 105.65% 103.65% 103.99% 98.82% 98.59% 99.55% 99.08% 96.08% 91.06% 93.31% 93.66%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,312.92% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,304.16% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8,281.55% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -96.30% -114.51% -189.59% -198.44% -188.72% -28.50% -21.07% -31.37% -47.07% -59.51% -71.45%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,733.40% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -51.82% -65.31% -78.94% -124.25% -122.15% -26.20% -20.09% -30.32% -46.01% -54.45% -61.55%
Return on Assets (ROA)		 -54.75% -67.95% -88.58% -124.44% -120.43% -26.12% -19.90% -29.13% -41.90% -50.81% -57.65%
Return on Common Equity (ROCE)		 -96.30% -114.51% -189.59% -198.44% -188.72% -28.50% -21.07% -31.37% -47.07% -59.51% -71.45%
Return on Equity Simple (ROE_SIMPLE)		 -56.41% -198.32% -382.82% -163.24% -224.50% -15.07% -20.15% -36.40% -59.42% -54.77% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -28 -18 -12 -12 -13 -20 -28 -32 -34 -34
NOPAT Margin		 -5,655.65% -7,374.44% -3,545.10% -3,155.33% -4,772.45% -3,650.33% -5,626.32% -7,236.11% -6,514.02% -4,986.19% -5,779.43%
Net Nonoperating Expense Percent (NNEP)		 -30.87% -30.68% -49.48% -49.31% -43.78% -8.42% -5.95% -8.76% -10.72% -13.66% -15.43%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -45.58% -41.06% -75.51%
Cost of Revenue to Revenue		 201.14% 454.12% 358.41% 157.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,531.82% 3,011.49% 2,816.14% 2,116.06% 2,354.92% 2,245.08% 3,297.49% 3,414.77% 2,672.75% 1,827.53% 2,398.65%
R&D to Revenue		 3,386.66% 3,938.01% 1,559.67% 2,157.94% 4,562.87% 3,069.67% 4,840.11% 7,022.54% 6,732.99% 5,395.61% 5,957.67%
Operating Expenses to Revenue		 7,979.26% 10,218.78% 4,806.01% 4,449.69% 6,917.79% 5,314.75% 8,137.60% 10,437.31% 9,405.74% 7,223.13% 8,356.32%
Earnings before Interest and Taxes (EBIT)		 -26 -38 -22 -16 -17 -19 -29 -40 -46 -49 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -36 -21 -16 -16 -19 -26 -39 -46 -49 -49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.30 3.25 1.80 1.20 1.31 4.96 1.69 0.59 0.95 2.68 4.17
Price to Tangible Book Value (P/TBV)		 3.30 3.25 1.80 1.20 1.31 4.96 1.69 0.59 0.95 2.68 4.17
Price to Revenue (P/Rev)		 513.09 168.71 23.18 31.93 39.24 1,736.31 662.14 162.04 135.50 324.92 319.20
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 349.99 112.67 9.54 1.66 0.00 1,378.44 269.88 0.00 0.00 190.59 220.88
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.34 0.84 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.23 0.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.11 -1.06 -1.08 -1.11 -1.24 -1.04 -1.01 -1.00 -1.02 -1.09 -1.17
Leverage Ratio		 1.76 1.69 2.14 1.59 1.57 1.09 1.06 1.08 1.12 1.17 1.24
Compound Leverage Factor		 1.86 1.75 2.23 1.58 1.55 1.09 1.05 1.03 1.02 1.09 1.16
Debt to Total Capital		 25.27% 45.55% 16.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 8.02% 6.50% 16.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 17.26% 39.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 74.73% 54.45% 83.01% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.65 -0.46 -0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.02 0.59 0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.44 -0.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.93 -0.59 -0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 2.88 0.76 0.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.64 -0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.91 -5.09 -23.89 -20.18 -24.93 56.30 13.69 0.15 -3.34 3.18 -4.60
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.34 5.00 2.40 4.37 2.37 21.79 22.28 14.25 7.41 7.08 3.67
Quick Ratio		 8.24 4.87 2.10 3.98 2.17 21.46 21.55 13.58 7.19 6.89 3.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -19 -29 -19 -11 -10 -13 -23 -29 -26 -30 -30
Operating Cash Flow to CapEx		 -990.35% -3,769.34% -23,383.72% 0.00% -19,620.09% -7,732.23% -11,239.02% -3,361.83% -5,307.04% -47,116.25% -86,188.64%
Free Cash Flow to Firm to Interest Expense		 -13.19 -17.22 -18.49 -431.21 0.00 -6,710.57 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -15.07 -18.54 -22.52 -519.46 0.00 -8,157.50 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -16.59 -19.03 -22.61 -518.56 0.00 -8,263.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.03 0.02 0.01 0.00 0.00 0.00 0.01 0.01
Accounts Receivable Turnover		 4.03 3.83 5.69 3.09 1.32 1.40 0.84 0.59 0.92 1.29 1.24
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.18 0.12 0.16 0.20 0.22 0.49 0.71 0.47 0.39 0.64 0.80
Accounts Payable Turnover		 0.70 1.59 1.85 0.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 90.68 95.40 64.11 118.11 276.95 261.02 434.64 617.47 396.04 283.50 293.91
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 518.81 229.00 197.04 455.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -428.13 -133.60 -132.93 -337.05 276.95 261.02 434.64 617.47 396.04 283.50 293.91
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.32 -1.59 -0.39 -1.37 -2.88 -2.82 -0.40 1.08 -5.08 -8.80 -13
Invested Capital Turnover		 -0.10 -0.20 -0.51 -0.43 -0.12 -0.13 -0.22 1.15 -0.24 -0.10 -0.05
Increase / (Decrease) in Invested Capital		 1.67 0.73 1.20 -0.98 -1.52 0.06 2.42 1.48 -6.16 -3.71 -4.12
Enterprise Value (EV)		 109 43 4.82 0.63 -0.59 505 97 -43 -8.70 130 131
Market Capitalization		 161 64 12 12 9.60 635 238 63 66 222 189
Book Value per Share		 $1.64 $0.65 $0.17 $0.44 $0.94 $3.63 $3.55 $2.38 $1.56 $1.62 $0.67
Tangible Book Value per Share		 $1.64 $0.65 $0.17 $0.44 $0.94 $3.63 $3.55 $2.38 $1.56 $1.62 $0.67
Total Capital		 65 36 7.84 10 7.31 128 140 106 70 83 45
Total Debt		 16 17 1.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 11 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -51 -21 -6.89 -11 -10 -131 -141 -105 -75 -92 -58
Capital Expenditures (CapEx)		 2.23 0.82 0.10 -0.02 0.07 0.21 0.21 1.01 0.58 0.08 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.09 -4.38 -1.37 -1.61 -3.62 -3.74 -1.25 -1.79 -7.85 -10 -15
Debt-free Net Working Capital (DFNWC)		 65 34 6.85 9.84 6.57 127 140 103 67 82 44
Net Working Capital (NWC)		 60 31 5.52 9.84 6.57 127 140 103 67 82 44
Net Nonoperating Expense (NNE)		 9.78 11 6.99 4.52 4.74 5.95 8.09 11 9.65 11 12
Net Nonoperating Obligations (NNO)		 -51 -21 -6.89 -11 -10 -131 -141 -105 -75 -92 -58
Total Depreciation and Amortization (D&A)		 0.72 1.35 1.37 0.86 0.49 0.47 2.06 0.87 -0.52 -0.19 -0.48
Debt-free, Cash-free Net Working Capital to Revenue		 -667.26% -1,149.41% -271.33% -425.87% -1,481.13% -1,022.95% -349.03% -463.99% -1,608.81% -1,481.70% -2,457.00%
Debt-free Net Working Capital to Revenue		 20,908.98% 8,794.41% 1,356.23% 2,601.45% 2,686.48% 34,764.21% 38,876.88% 26,807.25% 13,723.77% 11,951.10% 7,375.04%
Net Working Capital to Revenue		 19,238.38% 8,175.08% 1,092.77% 2,601.45% 2,686.48% 34,764.21% 38,876.88% 26,807.25% 13,723.77% 11,951.10% 7,375.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($75.60) ($93.60) ($51.84) ($8.26) ($2.80) ($1.08) ($0.73) ($0.89) ($0.93) ($0.95) ($0.69)
Adjusted Weighted Average Basic Shares Outstanding		 363.91K 419.10K 481.67K 2.33M 10.21M 37.05M 39.03M 43.60M 44.68M 47.65M 66.84M
Adjusted Diluted Earnings per Share		 ($87.12) ($98.64) ($51.84) ($8.26) ($2.80) ($1.08) ($0.73) ($0.89) ($0.93) ($0.95) ($0.69)
Adjusted Weighted Average Diluted Shares Outstanding		 367.39K 420.57K 481.67K 2.33M 10.21M 37.05M 39.03M 43.60M 44.68M 47.65M 66.84M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($2.80) ($1.08) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 413.30K 430.07K 767.92K 4.02M 5.97M 20.87M 43.31M 44.68M 44.68M 66.52M 68.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -28 -16 -11 -12 -13 -20 -28 -32 -34 -34
Normalized NOPAT Margin		 -5,655.65% -7,229.24% -3,243.96% -3,032.34% -4,772.45% -3,650.33% -5,626.32% -7,236.11% -6,514.02% -4,986.19% -5,779.43%
Pre Tax Income Margin		 -8,781.09% -10,249.77% -4,566.80% -4,293.22% -6,709.74% -5,267.49% -7,880.50% -10,026.94% -8,492.01% -6,651.68% -7,732.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -17.71 -22.51 -21.47 -646.87 0.00 -9,683.50 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -12.05 -16.78 -17.33 -469.81 0.00 -6,680.10 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -19.23 -23.00 -21.56 -645.97 0.00 -9,789.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -13.57 -17.28 -17.43 -468.91 0.00 -6,785.60 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.20% -3.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cardiff Oncology

This table displays calculated financial ratios and metrics derived from Cardiff Oncology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 44,677,169.00 44,677,169.00 44,677,169.00 44,724,591.00 46,549,634.00 - 66,524,294.00 66,525,854.00 66,525,854.00 67,360,564.00 68,364,979.00
DEI Adjusted Shares Outstanding		 44,677,169.00 44,677,169.00 44,677,169.00 44,724,591.00 46,549,634.00 - 66,524,294.00 66,525,854.00 66,525,854.00 67,360,564.00 68,364,979.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.22 -0.21 -0.22 -0.26 -0.25 - -0.20 -0.21 -0.17 -0.11 -0.18
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 51.61% 21.88% 146.99% 50.93% 17.02% -3.85% -46.83% -25.77% -27.27% 62.00% -62.39%
EBITDA Growth		 -24.57% -11.24% 11.27% -1.00% -13.76% -20.95% -31.56% -19.09% 4.11% 33.58% 10.93%
EBIT Growth		 -19.60% -9.62% 10.08% -3.11% -16.64% -21.55% -31.43% -17.44% 4.94% 37.74% 10.60%
NOPAT Growth		 -20.32% -10.01% 9.28% -2.76% -16.46% -21.68% -31.55% -17.79% 4.98% 37.74% 10.65%
Net Income Growth		 -13.53% -7.36% 10.80% -5.63% -21.83% -26.24% -34.19% -18.38% 5.04% 38.78% 8.11%
EPS Growth		 -10.00% -5.00% 12.00% -4.00% -13.64% -4.76% 9.09% 19.23% 32.00% 50.00% 10.00%
Operating Cash Flow Growth		 -6.29% 23.97% 10.61% -29.42% -31.41% -43.82% -65.30% 9.77% -3.62% 41.88% 3.96%
Free Cash Flow Firm Growth		 10.13% 86.69% 74.76% 48.82% 20.42% -374.39% -302.68% -60.13% -18.97% 73.27% 9.39%
Invested Capital Growth		 -224.11% -572.49% -1,253.33% -178.38% -134.02% -73.03% -43.19% -55.73% -42.61% -46.82% -25.92%
Revenue Q/Q Growth		 30.56% 10.64% 31.41% -20.49% 1.23% -9.09% -27.33% 11.01% -0.83% 102.50% -83.13%
EBITDA Q/Q Growth		 10.89% 5.05% -3.92% -14.86% -0.38% 0.13% -14.26% -3.96% 19.18% 30.82% -53.23%
EBIT Q/Q Growth		 11.51% 4.20% -5.72% -15.05% -0.10% 0.17% -14.32% -2.80% 18.97% 34.63% -64.17%
NOPAT Q/Q Growth		 11.37% 4.51% -5.82% -14.74% -0.45% 0.23% -14.40% -2.75% 18.97% 34.63% -64.18%
Net Income Q/Q Growth		 12.73% 4.05% -7.22% -17.65% -0.65% 0.57% -13.97% -3.79% 19.26% 35.90% -71.08%
EPS Q/Q Growth		 12.00% 4.55% -4.76% -18.18% 3.85% 12.00% 9.09% -5.00% 19.05% 35.29% -63.64%
Operating Cash Flow Q/Q Growth		 -11.57% 10.28% -8.42% -19.25% -13.28% 1.81% -24.61% 34.91% -30.09% 44.92% -105.93%
Free Cash Flow Firm Q/Q Growth		 29.05% 79.09% -70.19% -102.70% -10.33% -24.64% -44.46% 19.40% 18.03% 71.99% -389.67%
Invested Capital Q/Q Growth		 -24.11% -43.78% -23.78% -26.03% -4.34% -6.31% -2.43% -37.07% 4.45% -9.45% 12.15%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -7,803.55% -6,696.79% -5,296.10% -7,650.31% -7,586.06% -8,424.00% -13,104.59% -12,272.73% -10,001.67% -3,416.87% -31,031.71%
Operating Margin		 -7,673.76% -6,623.08% -5,333.17% -7,696.32% -7,636.97% -8,381.33% -13,194.50% -12,212.40% -9,978.33% -3,220.99% -31,341.46%
EBIT Margin		 -7,658.87% -6,631.41% -5,335.12% -7,719.63% -7,633.94% -8,382.67% -13,188.07% -12,213.22% -9,978.33% -3,221.40% -31,343.90%
Profit (Net Income) Margin		 -6,901.42% -5,985.26% -4,883.41% -7,225.77% -7,184.85% -7,858.00% -12,324.77% -11,523.14% -9,381.67% -2,969.55% -30,109.76%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 90.11% 90.26% 91.53% 93.60% 94.12% 93.74% 93.45% 94.35% 94.02% 92.18% 96.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -42.71% -47.07% -51.12% -58.80% -67.57% -59.51% -74.15% -91.93% -102.71% -71.45% -84.79%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -33.22% -32.72% -36.04% -62.79% -69.51% -64.03% -97.47% -93.89% -78.77% -24.02% -245.64%
Return on Assets (ROA)		 -29.94% -29.53% -32.99% -58.78% -65.42% -60.02% -91.09% -88.58% -74.06% -22.14% -235.97%
Return on Common Equity (ROCE)		 -42.71% -47.07% -51.12% -58.80% -67.57% -59.51% -74.15% -91.93% -102.71% -71.45% -84.79%
Return on Equity Simple (ROE_SIMPLE)		 -52.43% 0.00% -66.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.57 -7.23 -7.65 -8.78 -8.82 -8.80 -10 -10 -8.38 -5.48 -9.00
NOPAT Margin		 -5,371.63% -4,636.15% -3,733.22% -5,387.42% -5,345.88% -5,866.93% -9,236.15% -8,548.68% -6,984.83% -2,254.69% -21,939.02%
Net Nonoperating Expense Percent (NNEP)		 -2.20% -2.34% -2.87% -4.00% -4.37% -3.59% -4.58% -5.48% -4.86% -2.32% -5.32%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.37% -12.57% -16.76% -17.86% -10.61% -14.20% -17.65% -17.18% -12.07% -25.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,084.40% 1,746.79% 1,526.83% 1,972.39% 1,894.55% 2,007.33% 3,682.57% 2,742.15% 3,247.50% 1,232.51% 14,941.46%
R&D to Revenue		 5,689.36% 4,976.28% 3,906.34% 5,823.93% 5,842.42% 6,474.00% 9,611.93% 9,570.25% 6,830.83% 2,088.48% 16,500.00%
Operating Expenses to Revenue		 7,773.76% 6,723.08% 5,433.17% 7,796.32% 7,736.97% 8,481.33% 13,294.50% 12,312.40% 10,078.33% 3,320.99% 31,441.46%
Earnings before Interest and Taxes (EBIT)		 -11 -10 -11 -13 -13 -13 -14 -15 -12 -7.83 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -10 -11 -12 -13 -13 -14 -15 -12 -8.30 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.80 0.95 3.92 1.90 2.52 2.68 2.95 3.58 2.81 4.17 3.19
Price to Tangible Book Value (P/TBV)		 0.80 0.95 3.92 1.90 2.52 2.68 2.95 3.58 2.81 4.17 3.19
Price to Revenue (P/Rev)		 135.00 135.50 391.11 149.31 180.39 324.92 355.85 384.51 274.09 319.20 210.95
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 280.97 58.60 96.69 190.59 219.76 254.31 152.90 220.88 123.23
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.04 -1.08 -1.09 -1.09 -1.12 -1.18 -1.20 -1.17 -1.19
Leverage Ratio		 1.11 1.12 1.15 1.18 1.19 1.17 1.21 1.28 1.29 1.24 1.27
Compound Leverage Factor		 1.00 1.01 1.05 1.10 1.12 1.10 1.13 1.21 1.21 1.14 1.22
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.10 -1.92 4.76 -3.00 -2.52 4.40 2.86 0.00 -3.52 -2.40 -8.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.30 7.41 5.91 4.97 4.74 7.08 6.22 4.42 4.20 3.67 3.27
Quick Ratio		 9.04 7.19 5.71 4.85 4.65 6.89 6.04 4.29 4.14 3.57 3.20
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.13 -1.07 -1.83 -3.70 -4.08 -5.09 -7.35 -5.92 -4.86 -1.36 -6.66
Operating Cash Flow to CapEx		 -2,526.03% -89,237.50% -9,675.00% 0.00% 0.00% 0.00% 0.00% -32,030.77% -60,188.89% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Accounts Receivable Turnover		 1.08 0.92 1.14 2.17 1.69 1.29 1.47 1.12 1.15 1.24 1.76
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.35 0.39 0.48 0.54 0.60 0.64 0.59 0.59 0.60 0.80 0.81
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 336.43 396.04 319.82 167.95 216.14 283.50 248.10 327.16 318.28 293.91 207.18
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 336.43 396.04 319.82 167.95 216.14 283.50 248.10 327.16 318.28 293.91 207.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.54 -5.08 -6.29 -7.93 -8.28 -8.80 -9.01 -12 -12 -13 -11
Invested Capital Turnover		 -0.20 -0.24 -0.18 -0.12 -0.12 -0.10 -0.08 -0.05 -0.05 -0.05 -0.05
Increase / (Decrease) in Invested Capital		 -2.45 -6.16 -5.83 -5.08 -4.74 -3.71 -2.72 -4.42 -3.53 -4.12 -2.34
Enterprise Value (EV)		 -19 -8.70 171 39 67 130 129 139 76 131 65
Market Capitalization		 62 66 239 99 124 222 209 210 137 189 111
Book Value per Share		 $1.74 $1.56 $1.36 $1.17 $1.06 $1.62 $1.07 $0.88 $0.73 $0.67 $0.51
Tangible Book Value per Share		 $1.74 $1.56 $1.36 $1.17 $1.06 $1.62 $1.07 $0.88 $0.73 $0.67 $0.51
Total Capital		 78 70 61 52 49 83 71 59 49 45 35
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -81 -75 -67 -60 -58 -92 -80 -71 -61 -58 -46
Capital Expenditures (CapEx)		 0.32 0.01 0.08 0.00 0.00 0.00 0.00 0.03 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.48 -7.85 -9.04 -11 -11 -10 -10 -14 -13 -15 -13
Debt-free Net Working Capital (DFNWC)		 75 67 58 50 47 82 69 57 47 44 33
Net Working Capital (NWC)		 75 67 58 50 47 82 69 57 47 44 33
Net Nonoperating Expense (NNE)		 2.16 2.10 2.36 3.00 3.03 2.99 3.37 3.60 2.88 1.74 3.35
Net Nonoperating Obligations (NNO)		 -81 -75 -67 -60 -58 -92 -80 -71 -61 -58 -46
Total Depreciation and Amortization (D&A)		 -0.20 -0.10 0.08 0.11 0.08 -0.06 0.09 -0.07 -0.03 -0.48 0.13
Debt-free, Cash-free Net Working Capital to Revenue		 -1,407.83% -1,608.81% -1,481.97% -1,593.23% -1,576.20% -1,481.70% -1,783.13% -2,555.96% -2,699.20% -2,457.00% -2,509.90%
Debt-free Net Working Capital to Revenue		 16,279.78% 13,723.77% 9,532.30% 7,477.29% 6,793.47% 11,951.10% 11,826.24% 10,463.67% 9,419.00% 7,375.04% 6,262.67%
Net Working Capital to Revenue		 16,279.78% 13,723.77% 9,532.30% 7,477.29% 6,793.47% 11,951.10% 11,826.24% 10,463.67% 9,419.00% 7,375.04% 6,262.67%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.22) ($0.21) ($0.22) ($0.26) ($0.25) ($0.22) ($0.20) ($0.21) ($0.17) ($0.11) ($0.18)
Adjusted Weighted Average Basic Shares Outstanding		 44.68M 44.68M 44.68M 44.83M 46.87M 47.65M 66.52M 66.53M 66.88M 66.84M 68.35M
Adjusted Diluted Earnings per Share		 ($0.22) ($0.21) ($0.22) ($0.26) ($0.25) ($0.22) ($0.20) ($0.21) ($0.17) ($0.11) ($0.18)
Adjusted Weighted Average Diluted Shares Outstanding		 44.68M 44.68M 44.68M 44.83M 46.87M 47.65M 66.52M 66.53M 66.88M 66.84M 68.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 44.68M 44.68M 44.72M 46.55M 51.13M 66.52M 66.53M 66.53M 67.36M 68.36M 68.37M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.57 -7.23 -7.65 -8.78 -8.82 -8.80 -10 -10 -8.38 -5.48 -9.00
Normalized NOPAT Margin		 -5,371.63% -4,636.15% -3,733.22% -5,387.42% -5,345.88% -5,866.93% -9,236.15% -8,548.68% -6,984.83% -2,254.69% -21,939.02%
Pre Tax Income Margin		 -6,901.42% -5,985.26% -4,883.41% -7,225.77% -7,184.85% -7,858.00% -12,324.77% -11,523.14% -9,381.67% -2,969.55% -30,109.76%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Cardiff Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cardiff Oncology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cardiff Oncology's net income appears to be on an upward trend, with a most recent value of -$45.85 million in 2025, rising from -$27.47 million in 2015. The previous period was -$45.43 million in 2024. Find out what analysts predict for Cardiff Oncology in the coming months.

Cardiff Oncology's total operating income in 2025 was -$48.96 million, based on the following breakdown:
  • Total Gross Profit: $593 thousand
  • Total Operating Expenses: $49.55 million

Over the last 10 years, Cardiff Oncology's total revenue changed from $312.81 thousand in 2015 to $593 thousand in 2025, a change of 89.6%.

Cardiff Oncology's total liabilities were at $16.50 million at the end of 2025, a 15.8% increase from 2024, and a 27.5% decrease since 2015.

In the past 10 years, Cardiff Oncology's cash and equivalents has ranged from $8.23 million in 2017 to $130.98 million in 2020, and is currently $17.47 million as of their latest financial filing in 2025.

Over the last 10 years, Cardiff Oncology's book value per share changed from 1.64 in 2015 to 0.67 in 2025, a change of -58.9%.


Related Companies

Financial statements for NASDAQ:CRDF last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel